| Literature DB >> 35770044 |
Li Liu1, Xi Zhang1, Xin Xing1, Ismail Mohammed1, Xiao-Ting Xu1, Zhen-Zhou Jiang1,2, Tao Wang1,2, Xin Huang1,2, Xin-Zhi Wang1,2, Lu-Yong Zhang1,3, Li-Xin Sun1,2.
Abstract
Triptolide (TP) has limited usage in clinical practice due to its side effects and toxicity, especially liver injury. Hepatic macrophages, key player of liver innate immunity, were found to be recruited and activated by TP in our previous study. The nuclear factor-erythroid-2-related factor 2 (Nrf2) pathway exerts a protective role in TP-induced liver damage, but its effect on the functions of hepatic macrophage has not been elucidated. Here, we determined whether TP can regulate the recruitment and polarization of hepatic macrophages by inhibiting Nrf2 signaling cascade. Our results demonstrated that TP inhibited the Nrf2 signaling pathway in hepatic macrophages. The changes in hepatic macrophages were responsible for the increased susceptibility toward inflammatory stimuli, and hence, TP pretreatment could induce severe liver damage upon the stimulation of a nontoxic dose of lipopolysaccharides. In addition, the Nrf2 agonist protected macrophages from TP-induced toxicity and Nrf2 deficiency significantly aggravated liver injury by enhancing the recruitment and M1 polarization of hepatic macrophages. This study suggests that Nrf2 pathway-mediated hepatic macrophage polarization plays an essential role in TP-induced liver damage, which can serve as a potential therapeutic target for preventing hepatotoxicity induced by TP.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35770044 PMCID: PMC9236772 DOI: 10.1155/2022/1492239
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1Effects of TP on the Nrf2 signal pathway both in vivo and in vitro. (a) Comparison of Nrf2 mRNA expression in primary hepatocytes (HCs) and Kupffer cells (KCs) (n = 5). (b) Changes on the viability of Raw264.7 cells administrated with different concentrations of TP for 24 hours (n = 6). (c) Effect of TP on the transportation of Nrf2 to the nucleus in Raw264.7 cells (n = 3). (d) Changes of Nrf2 and NQO1 in the liver of mice after TP treatment for 14 days (n ≥ 5). (e) Changes in the serum ALT and AST in female and male mice administrated with TP for 14 days (n = 6). (f) Representative images of HE-stained livers from female and male mice; inflammatory infiltration (black arrows), 200x magnification. Data are presented as mean ± SEM, ∗P < 0.05 and ∗∗P < 0.01 vs. control.
Figure 2Nrf2 agonist protects macrophages from TP-induced toxicity and inhibits M1 polarization. (a) Effect of SFN on Raw264.7 cell viability after TP treatment (n = 6). (b) Effect of SFN on the Nrf2 signaling pathway in Raw264.7 cells (n = 6). (c) Changes in M1 macrophages in Raw264.7 cells after SFN pretreatment. Data are presented as mean ± SEM, ∗P < 0.05 and ∗∗P < 0.01 vs. TP.
Figure 3Effects of TP on the ROS pathway in Nrf2−/− mice. (a) The proportion of F4/80+DCFH-DA+macrophages in the liver (n = 5). (b) Changes in the protein expression of ROS-related pathways in the liver (n = 3). Data are presented as the mean ± SEM, ∗P < 0.05 vs. control, ∗∗P < 0.01 vs. WT-Con.
Figure 4Effects of TP on macrophages in Nrf2−/− mice. (a) Changes in the proportion of monocyte-derived macrophages (F4/80+CD11b+) in WT and Nrf2−/− mice administrated with TP for 14 days (n = 5). (b) Changes in the proportion of M2 macrophages (F4/80+CD206+) in WT and Nrf2−/− mice administrated with TP for 14 days (n = 5). (c) Changes in the proportion of M1 macrophages (F4/80+CD86+) in WT and Nrf2−/− mice administrated with TP for 14 days (n = 5). (d) Changes in the proportion of activated macrophages (F4/80+CD68+) in WT and Nrf2−/− mice administrated with TP for 14 days (n = 5). Data are presented as mean ± SEM, ∗P < 0.05 vs. WT-TP.
Figure 5Nrf2 deficiency further promotes M1 polarization in LPS-stimulated mice after TP pretreatment. (a) F4/80 Immunofluorescent staining of the liver. Data are representative of experiments (DAPI: nucleus, F4/80: macrophages). (b) Changes in the proportion of monocyte-derived macrophages (F4/80+CD11b+) in Nrf2−/− mice administrated with TP and LPS (n = 5). (c) Changes in the proportion of liver M1 (F4/80+CD86+) and M2 (F4/80+CD206+) macrophages in Nrf2−/− mice administrated with TP and LPS (n = 5). Data are presented as mean ± SEM, ∗P < 0.05 and ∗∗P < 0.01 vs. WT-control.
Figure 6Nrf2 deficiency aggravates the liver injury induced by LPS stimulation after TP pretreatment. (a) Changes in the levels of ALT and AST in WT and Nrf2−/− mice treated with TP and LPS (n = 6). (b) Representative images of HE-stained liver from WT and Nrf2−/− mice treated with TP and LPS, 200x magnification. (c) RT-PCR analysis of hepatic M1 genes in WT and Nrf2−/− mice administrated with TP and LPS (n = 6). Data are presented as mean ± SEM, ∗P < 0.05 and ∗∗P < 0.01 vs. WT-control.